Engflag

Cystocalm

Quick links to important sections

Cystocalm

Cystocalm_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cystocalm

What is Cystocalm?

Cystocalm is an oral medication specifically formulated to provide symptomatic relief for women experiencing the discomfort associated with acute cystitis. Cystitis is an inflammation of the bladder, typically caused by a minor urinary tract infection, which leads to increased acidity in the urine.

Active Ingredient and Mechanism

The primary active component of Cystocalm is sodium citrate. This substance belongs to a group of medications known as urinary alkalinizers. Its function is to reduce the acidity of the urine. When the urine becomes less acidic, it causes less irritation to the inflamed lining of the bladder and urethra during urination.

Purpose of Use

Cystocalm is used to manage the localized symptoms of a bladder infection rather than treating the underlying bacterial cause. It is designed for short-term use to alleviate specific sensations, including:

  • Burning or stinging pain when passing water.
  • The urgent need to urinate more frequently than usual.
  • General discomfort in the lower pelvic region related to bladder irritation.

By neutralizing excess acid, the medication helps make the process of urination more comfortable while the body or other treatments address the infection.

Regulatory References

  1. National Library of Medicine (NIH)

What side effects are possible with Cystocalm?

Possible side effects and safety information

The safety profile for Cystocalm (Cysteamine Bitartrate) is documented in regulatory labeling and includes adverse reactions primarily affecting the Gastrointestinal and Nervous Systems.

Regulatory Classification of Adverse Reactions

Adverse effects are classified by frequency based on official data, with the highest incidence rates falling into the Very Common and Common categories:

  • Very Common (affecting more than 1 in 10 patients): Vomiting, Nausea, Diarrhea, Anorexia (loss of appetite), Lethargy, and Pyrexia (fever).
  • Common (affecting 1 to 10 in 100 patients): Abdominal pain, Headache, Encephalopathy (brain function disorder), Rash, and Dyspepsia (indigestion).

Serious Adverse Reactions and Safety Constraints

The regulatory profile identifies specific Serious Adverse Reactions. These include the potential for Gastrointestinal Ulceration and Bleeding, severe skin reactions such as Toxic Epidermal Necrolysis, and neurological complications like Benign Intracranial Hypertension (Pseudotumor Cerebri). Other serious events involve bone and joint abnormalities (e.g., osteopenia, compression fractures), particularly in pediatric patients treated with high doses.

Safety Restrictions: Cystocalm is contraindicated in individuals with a history of serious hypersensitivity to either cysteamine or penicillamine. Furthermore, use is not recommended for women who are breastfeeding due to potential risk to the infant, as stated in official labeling. Adverse reactions may be more pronounced at the initiation of therapy, as documented in regulatory sources.

Overdose and Emergency Response

Overdose with Cysteamine Bitartrate is primarily defined by the onset of severe clinical manifestations, requiring prompt action. Officially documented signs of overdose and high-dose toxicity include vomiting and progressive lethargy or excessive sleepiness. More serious clinical outcomes associated with systemic toxicity may include seizures and severe central nervous system effects such as encephalopathy. Gastrointestinal toxicity, specifically ulceration and bleeding, is also noted in regulatory documentation as a potential severe complication of high exposure.

When to Seek Help

Immediate medical attention is required for any suspected overdose. Regulatory guidance mandates that individuals must seek immediate medical attention or call emergency services if severe symptoms, such as trouble breathing or passing out, are observed. Contacting a poison control center is also a specified emergency procedure.

Supportive Management

The management of a Cysteamine overdose is defined by the absence of a specific antidote, as no specific agent is known to reverse its effects. Consequently, the required treatment is symptomatic and supportive. This includes the appropriate support and monitoring of vital organ functions, such as the cardiovascular and respiratory systems. Continuous observation is necessary to monitor for potential severe complications and systemic toxicity, exactly as outlined in official prescribing information.

Therapeutic Uses of Cystocalm

What Cystocalm Treats: Main Uses and Benefits

Cystocalm (Cysteamine Bitartrate) is commonly used in the chronic management of Nephropathic Cystinosis, a rare, inherited metabolic disorder, which may be associated with symptoms related to systemic imbalance and progressive organ dysfunction. The medication is considered relevant for the treatment of this condition, and its use is associated with supporting kidney function and may contribute to delaying the progression toward renal failure. It is relevant in contexts involving heightened systemic burden and is used for managing the progression of the condition.

Therapeutic Indications and Core Benefits

Cystocalm is applied in addressing manifestations across key areas: preserving kidney health, supporting growth and development in children, and managing ocular and systemic symptoms. The medication supports patients during difficult episodes and is relevant in contexts involving heightened systemic burden. “It is applied in clinical settings that involve chronic, systemic symptom patterns, which is generally applied in contexts where additional symptomatic support is needed over time.”

In pediatric patients, the drug is relevant for easing developmental deficits, helping to address the clinical syndrome of impaired growth. This therapy contributes to easing the overall symptom load and may assist with addressing developmental deficits. The medication supports patients during phases of increased distress or discomfort.

Quick Fact: Relief for Ocular Symptoms

The medication plays a role in managing light sensitivity and other discomforts caused by crystal deposits in the eyes, which helps improve day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cystocalm?

Cystocalm (Cysteamine Bitartrate) is officially indicated for the chronic management of Nephropathic Cystinosis. The eligible population includes adults and pediatric patients 1 year of age and older (for the delayed-release formulation). The eligibility profile is strictly defined by regulatory bodies.

Absolute Contraindications

The medicine must not be used by individuals with a known hypersensitivity (allergy) to Cysteamine or to Penicillamine. Furthermore, use is contraindicated in women who are breastfeeding due to the potential risk to the infant, as stated in regulatory labels.

Age and Condition Restrictions

The safety and efficacy of the medication have not been established for children younger than 1 year of age. For children under the age of approximately six, intact capsules must not be given due to the risk of aspiration.

Use requires careful monitoring in patients with pre-existing hepatic or renal impairment and those with a history of gastrointestinal ulceration or bleeding. The medicine is generally not recommended during pregnancy unless the clinical necessity clearly outweighs the potential for fetal risk.

What should I know about interactions with other medicines?

The official regulatory documents for Cystocalm (Cysteamine Bitartrate) define its interaction profile through a formal contraindication and specific pharmacokinetic constraints, particularly for the delayed-release formulation.

Contraindicated Combinations

The use of this medication is formally contraindicated in patients with a history of serious hypersensitivity reaction, including anaphylaxis, to the medicinal product Penicillamine or to Cysteamine itself. This prohibition is based on a recognized risk of cross-sensitivity.

Pharmacokinetic and Timing Restrictions

The delayed-release formulation has documented pharmacokinetic alterations when co-administered with substances that increase gastric pH, such as medications containing bicarbonate or carbonate. This interaction may cause the premature release of the drug, which is associated with an increase in White Blood Cell (WBC) cystine concentration. To avoid this altered exposure, the delayed-release product must be taken at least 1 hour before or 1 hour after these pH-increasing agents.

Food and Substance Avoidance

The official labeling includes restrictions for specific non-medicinal substances. Consumption of alcohol must be avoided during treatment with the delayed-release formulation, as it may adversely affect the drug's release rate and overall pharmacokinetic properties. Additionally, the consumption of high-fat foods must be avoided within one hour before or one hour after taking the delayed-release capsule. Conversely, necessary concurrent therapies, such as electrolyte replacements, Vitamin D, and thyroid hormone, are explicitly stated to be administered concomitantly.

Mechanism of Action

How Cystocalm Works

The mechanism of Cysteamine (Cystocalm) is centered on a targeted molecular transport system that influences a key chemical process within the cell's waste compartments, known as lysosomes.

Molecular Intervention and Transport Conversion

Cysteamine is an aminothiol that chemically reacts with the accumulated cystine within the lysosome via a thiol-disulfide interchange reaction, converting the cystine into a Mixed Disulfide molecule and Cysteine. This molecular conversion permits the subsequent exit of the molecules via alternative, functional transporters (like PQLC2) that would otherwise not recognize the cystine substrate.

️ Preventing Solute Aggregation and Modulating Redox Balance

By continuously reducing the concentration of intralysosomal cystine, the mechanism prevents the physical aggregation of cystine into cytotoxic crystals. Furthermore, the resulting Cysteine is utilized in the synthesis of the antioxidant Glutathione, thereby mitigating the associated oxidative stress.

Mechanistic Constraints

The mechanism of depletion is constrained by its concentration in and penetration into target tissue. The depletion is less effective in avascular tissues (those lacking blood vessels) because the systemically administered Cysteamine concentration is insufficient for the necessary chemical conversion and transport in these areas.

Dosage and Administration Information

Cystocalm (Cysteamine Bitartrate) is administered orally and is supplied in both Immediate-Release (IR) and Delayed-Release (DR) capsule formulations, each requiring specific administration protocols. While the primary route is oral, administration via a gastrostomy tube is an approved option for the contents of the Delayed-Release formulation.

Treatment is intended for chronic, long-term use and follows a pattern of gradual dose escalation. The initial dose is a fractional amount of the total maintenance dose, which is gradually increased over approximately four to six weeks. The final dose is calculated based on Body Surface Area (BSA) at 1.3 g/m^2 /day for pediatric patients, with adult regimens based on BSA or a 2 g/day dose for the Immediate-Release form. Dosage adjustments are mandatory and must be guided by therapeutic monitoring, specifically the measurement of White Blood Cell cystine levels.

The dosing frequency and relationship to food differ by formulation. The Immediate-Release capsule is administered in four divided doses daily (every six hours) and may be taken with or without food. Conversely, the Delayed-Release capsule is taken in two divided doses daily (every twelve hours) and requires strict timing: it must be administered at least two hours after eating and 30 minutes before eating. The official label specifies that Delayed-Release capsules must not be crushed or chewed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cystocalm

The information below summarizes the types of research and observed patterns for Cystocalm (Cysteamine Bitartrate). It describes what has been studied and what remains uncertain, and it is not a guide for treatment or dosing.

Evidence for Use in Chronic Management of Nephropathic Cystinosis

The primary evidence base for Cystocalm was evaluated through research examining its long-term association with patterns of body metabolism and organ health. Because Nephropathic Cystinosis is a rare disorder, the immediate-release formulation relies mainly on long-term observational cohort studies and retrospective analyses rather than large controlled trials against no treatment. Studies monitored outcomes like Estimated Glomerular Filtration Rate (eGFR) and the White Blood Cell (WBC) Cystine level. Long-term studies described patient patterns where the time elapsed before reaching ESRD was observed to be longer in those receiving the medication compared to historical patient cohorts. This observational data provides a moderate level of certainty.

Evidence in Pediatric Patients for Growth and Development

The research exploring physical development in children receiving Cystocalm monitored linear growth measurements observed during therapeutic use, mainly through long-term open-label extension studies. Findings describe patterns where pediatric patients receiving the therapy showed linear growth measurements during the study period, contributing to understanding symptom patterns.

Evidence for Ocular Symptoms and Corneal Deposits

Research explored patterns related to crystal deposits in the eyes. Studies monitored the density and depth of Corneal Cystine Crystals using retrospective observational analyses. Findings describe patterns related to crystal score measurements over time. It is important to note that data for the oral drug's direct impact on ocular outcomes is limited and has a low level of certainty, as many observations are associated with topical cysteamine formulations (eye drops).

Evidence Gaps and Areas of Research Uncertainty

One significant limitation is the absence of a foundational prospective, controlled trial against placebo/no treatment for the immediate-release formulation. The evidence is therefore dependent on long-term observational patterns. Additionally, because the condition is so rare, sample sizes were modest in many studies, and data for certain groups remain limited. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Cystocalm (FAQ)

Q: Are there any specific foods or drinks that should be avoided while taking Cystocalm?

A: Yes, official product information outlines specific restrictions, particularly for the delayed-release formulation. The official product information states that high-fat foods should be avoided within one hour before or one hour after taking the delayed-release capsule. The labeling also states that alcohol should be avoided entirely during treatment with the delayed-release formulation.

Q: What are the signs that Cystocalm might not be working for me?

A: Cystocalm is a medication used for chronic management, and its therapeutic effectiveness is monitored through regular laboratory tests. According to regulatory documents, dose adjustments are mandatory and are guided by therapeutic monitoring, specifically by measuring White Blood Cell cystine levels. A consistent pattern of high White Blood Cell cystine levels, as determined by laboratory monitoring, is used to determine the need for therapeutic adjustment. Clinical decisions based on these levels should be discussed with a healthcare provider.

Q: Can older adults safely use Cystocalm?

A: Official labeling indicates that Cystocalm is indicated for adults. While the medicine is used by the geriatric population, specific information on dose adjustments or unique precautions solely for patients over 65 is not detailed in the official product information.

Q: Do I need a prescription to buy Cystocalm, or is it over the counter?

A: Cystocalm is classified as a specialized prescription medication. It is not available for purchase over the counter and requires a valid prescription from a qualified healthcare provider.

Q: Will Cystocalm interfere with my sleep or cause insomnia?

A: Regulatory documents list central nervous system effects as potential adverse reactions. These reactions include lethargy (a state of tiredness or lack of energy) and headache. If you experience these effects, they may impact your rest or sleep.

Q: Is Cystocalm marketed as a cure, or just a management aid?

A: According to the official product information, Cystocalm is indicated for the chronic management of Nephropathic Cystinosis. It is considered a long-term treatment used to manage the underlying metabolic disorder.

Q: Are there different strengths or formulations of Cystocalm available?

A: Yes, the medicine is supplied in two different forms: an Immediate-Release (IR) capsule and a Delayed-Release (DR) capsule formulation. These two formulations have different administration requirements and dosing frequencies.

Q: Is Cystocalm safe for teenagers to use?

A: Official regulatory documents indicate that Cystocalm is indicated for pediatric patients one year of age and older. The medicine is indicated for this age group, as its safety and efficacy have been studied in this population.

Q: Can Cystocalm be crushed or opened if someone has trouble swallowing pills?

A: This depends on the specific formulation. The official label specifies that the Delayed-Release capsules should not be crushed or chewed to ensure the medicine works as intended. However, the contents of the Delayed-Release formulation may be administered via a gastrostomy tube if medically necessary.

Q: Is it better to take Cystocalm with food or on an empty stomach?

A: This depends on the specific formulation. The Immediate-Release capsule may be taken with or without food. In contrast, the Delayed-Release capsule requires strict timing: it should be administered at least two hours after eating and 30 minutes before eating.

Q: What do regulatory warnings say about using Cystocalm if there is a history of stomach ulcers?

A: Official warnings state that the medicine should be used with careful monitoring in patients with a pre-existing history of gastrointestinal ulceration or bleeding. Gastrointestinal ulceration is also listed as a potential serious adverse reaction in regulatory documents.

Q: Can you take Cystocalm while traveling or across different time zones?

A: The administration of Cystocalm requires adherence to a fixed schedule. The Immediate-Release capsule is administered four times daily (every six hours), and the Delayed-Release capsule is administered twice daily (every twelve hours). Adhering to this fixed schedule is important to maintain consistent drug levels, which should be considered when adjusting for different time zones.

Q: Is it normal to feel a slight stomach upset when you first start taking Cystocalm?

A: Gastrointestinal issues, including vomiting, nausea, and diarrhea, are listed in regulatory documents as Very Common adverse reactions. Official safety information states that these effects may be more noticeable at the initiation of therapy when the body is adjusting to the medicine.

Q: Can men take Cystocalm, or is it only meant for women?

A: Cystocalm is indicated for use in all adults and pediatric patients one year of age and older, and there are no specific exclusions for adult men. The only gender-specific restriction noted in the label is that the medicine is contraindicated in women who are breastfeeding.

Q: Does Cystocalm cause drowsiness or make it unsafe to drive?

A: The medicine is associated with Central Nervous System adverse reactions, such as lethargy and encephalopathy (a brain function disorder). Because the medicine is associated with these effects, caution is generally recommended when driving or operating machinery.

Q: Are there any warnings for people with kidney or liver issues using Cystocalm?

A: Yes, official product warnings state that careful monitoring is required when the medicine is used in patients who have pre-existing hepatic (liver) or renal (kidney) impairment.

Q: Is it safe to drink alcohol in moderation while taking Cystocalm?

A: Official product information states that alcohol should be avoided during treatment with the delayed-release formulation. This restriction is in place because alcohol may negatively affect the drug's release rate and overall absorption.

Q: Does Cystocalm need to be stored in the refrigerator?

A: Official storage instructions state that the medicine must be stored at a temperature that does not exceed 25 C (77 F). It is required to be kept tightly closed to protect the capsules from light and moisture. Refrigeration is not required, as long as the storage temperature does not exceed 25 C (77 F).

Q: Are there any known severe allergic reaction signs to watch out for with Cystocalm?

A: The medicine is formally contraindicated in patients with a history of serious hypersensitivity (allergic) reaction, including anaphylaxis. This includes a known history of severe allergy to either Cysteamine or the related medicine Penicillamine.

How should Cystocalm be stored and disposed of?

Storage and Disposal Requirements for Cystocalm

The storage conditions for Cystocalm (Cysteamine Bitartrate) are strictly defined to maintain the product's stability and efficacy. The medicine must be stored at a temperature that does not exceed 25 C and must be kept out of the sight and reach of children.

Handling and Stability

To prevent degradation, the container must be kept tightly closed to protect the capsules from both light and moisture. The included desiccant unit must remain inside the bottle. The medicine must not be used after the expiry date printed on the label, which marks the end of its two-year shelf life.

Disposal

Official disposal rules forbid throwing the unused or expired product into wastewater or household waste. Patients must ask a pharmacist how to properly discard the medicine to ensure compliance with pharmaceutical waste management regulations and to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cystocalm found in:

A-Z Index: